{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:14:27Z","timestamp":1789496067556,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100026248","name":"Poetry Society of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026248","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nimbus Discovery, Inc."},{"DOI":"10.13039\/100005120","name":"Warner Bros. Discovery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021201","name":"European Academy of Dermatology and Venereology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021201","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005629","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005629","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ard.2025.05.023","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:22:09Z","timestamp":1751581329000},"page":"1660-1674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-1310","authenticated-orcid":false,"given":"Alan","family":"Kivitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8916-3680","authenticated-orcid":false,"given":"Elena Tomaselli","family":"Muensterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-5830","authenticated-orcid":false,"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-6203","authenticated-orcid":false,"given":"Piotr A","family":"Klimiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4283-9683","authenticated-orcid":false,"given":"Guillermo","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9363-145X","authenticated-orcid":false,"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9859-4203","authenticated-orcid":false,"given":"Bhaskar","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8877-1384","authenticated-orcid":false,"given":"Sue","family":"Dasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6419-425X","authenticated-orcid":false,"given":"Xinyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7464-3462","authenticated-orcid":false,"given":"Ting","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-9255","authenticated-orcid":false,"given":"Jingjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0531-4127","authenticated-orcid":false,"given":"Peter","family":"Pothula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8484-3955","authenticated-orcid":false,"given":"Haoling Holly","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4586-0619","authenticated-orcid":false,"given":"Mona","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0696-4129","authenticated-orcid":false,"given":"Apinya","family":"Lertratanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.05.023_bib0001","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.05.023_bib0002","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.05.023_bib0003","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.05.023_bib0004","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.05.023_bib0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ard.2025.05.023_bib0006","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.05.023_bib0007","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.05.023_bib0008","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ard.2025.05.023_bib0009","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.2147\/JIR.S380686","article-title":"TYK2 in immune responses and treatment of psoriasis","volume":"15","author":"Shang","year":"2022","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.ard.2025.05.023_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4331\/wjbc.v13.i1.1","article-title":"Current understanding of the role of tyrosine kinase 2 signaling in immune responses","volume":"13","author":"Muromoto","year":"2022","journal-title":"World J Biol Chem"},{"key":"10.1016\/j.ard.2025.05.023_bib0011","doi-asserted-by":"crossref","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ard.2025.05.023_bib0012","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2217\/imt-2021-0096","article-title":"TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases","volume":"13","author":"Gonciarz","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ard.2025.05.023_bib0013","series-title":"Presented at the American Academy of Dermatology","article-title":"Analysis of histologic, molecular and clinical improvement in moderate-to-severe psoriasis: results from a phase 1b trial of the novel allosteric TYK2 inhibitor NDI-034858 [poster]","author":"McElwee","year":"2022"},{"key":"10.1016\/j.ard.2025.05.023_bib0014","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","article-title":"Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279","volume":"66","author":"Leit","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.ard.2025.05.023_bib0015","article-title":"Pharmacological characterization of zasocitinib (TAK-279): an oral, highly selective and potent allosteric TYK2 inhibitor","author":"Mehrotra","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ard.2025.05.023_bib0016","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ard.2025.05.023_bib0017","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active psoriatic arthritis [Internet]. 2024 [cited 2025 May]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05153148"},{"key":"10.1016\/j.ard.2025.05.023_bib0018","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40744-023-00535-3","article-title":"Psoriatic arthritis in males and females: differences and similarities","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ard.2025.05.023_bib0019","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13075-021-02680-y","article-title":"Sex-specific differences and how to handle them in early psoriatic arthritis","volume":"24","author":"Passia","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.05.023_bib0020","first-page":"76","article-title":"Sex-related differences in baseline patient and disease characteristics: post hoc analyses of three phase 3, randomized, double-blind, placebo-controlled studies in patients with active psoriatic arthritis [abstract]","author":"Coates","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.05.023_bib0021","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40744-024-00678-x","article-title":"Gender differences in perceptions of psoriatic arthritis disease impact, management, and physician interactions: results from a global patient survey","volume":"11","author":"Eder","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ard.2025.05.023_bib0022","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","article-title":"Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis","volume":"5","author":"Eder","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.05.023_bib0023","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1136\/annrheumdis-2024-eular.369","article-title":"AB0403 influence of body weight, sex and prior biologic history on treatment outcomes associated with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in a phase 2b randomized trial in patients with active psoriatic arthritis","volume":"83","author":"Eder","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.05.023_bib0024","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.05.023_bib0025","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.05.023_bib0026","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.05.023_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001756","article-title":"Systematic review of the use of CRP in clinical trials for psoriatic arthritis: a concern for clinical practice?","volume":"8","author":"Houttekiet","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.05.023_bib0028","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl 2","key":"10.1016\/j.ard.2025.05.023_bib0029","article-title":"Consensus exercise on domains in psoriatic arthritis","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.05.023_bib0030","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/pds.3447","article-title":"Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996\u20132009","volume":"22","author":"Asgari","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ard.2025.05.023_bib0031","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s13555-021-00564-2","article-title":"Correlation between change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of secukinumab","volume":"11","author":"Houghton","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ard.2025.05.023_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105534","article-title":"Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe","volume":"90","author":"Walsh","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ard.2025.05.023_bib0033","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40744-020-00221-8","article-title":"Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey","volume":"7","author":"Tillett","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ard.2025.05.023_bib0034","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00403-019-01906-z","article-title":"Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)","volume":"311","author":"Duvetorp","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ard.2025.05.023_bib0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40744-018-0120-8","article-title":"Skin involvement in psoriatic arthritis worsens overall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational, cross-sectional study","volume":"5","author":"de Vlam","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ard.2025.05.023_bib0036","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3899\/jrheum.150626","article-title":"Toward treating to target in psoriatic arthritis","volume":"93","author":"Gladman","year":"2015","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.ard.2025.05.023_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001083","article-title":"Treat-to-target in PsA: methods and necessity","volume":"6","author":"Dures","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.05.023_bib0038","series-title":"Presented at the Society for Investigative Dermatology","article-title":"Characterization of pharmacokinetics, pharmacodynamics, tolerability and clinical activity in Phase I studies of the novel allosteric tyrosine kinase 2 (TYK2) inhibitor NDI-034858 [poster]","author":"Gangolli","year":"2022"},{"key":"10.1016\/j.ard.2025.05.023_bib0039","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/rheumatology\/keab774","article-title":"Placebo response in psoriatic arthritis clinical trials: a systematic review and meta-analysis","volume":"61","author":"Erre","year":"2022","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725010416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725010416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T08:01:18Z","timestamp":1777190478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725010416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0003496725010416"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.05.023","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}